Comparative Pharmacology
Head-to-head clinical analysis: NUZYRA versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUZYRA versus SUMYCIN.
NUZYRA vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic